-
– Phase 3 Clinical Trial Demonstrated the Safety Profile of Veklury in Patients with Severe Renal Impairment – – Real-World Evidence Demonstrated Veklury Reduced COVID-19- ...
-
– Agreement Enables Rapid and Equitable Access to the Clinical Benefits of Veklury for Appropriate COVID-19 Patients in the Majority of Countries of the EU and EEA – – ...
-
Gilead Sciences Update on Supply and Distribution of Veklury® (remdesivir) in the United States
-- Supply of Veklury Is Meeting Real-Time Demand in the U.S. -- -- Clinical Benefits of Veklury Consistently Demonstrated Across Three Randomized, Clinical Trials Are Now Available to ...
-
– Double-Blind Placebo-Controlled Study Evaluated the Efficacy of Early Use of Veklury IV in Non-Hospitalized Patients – – Late-breaking Data to be Presented at IDWeek 2021 – ...
-
-- New Agreement Continues to Enable Rapid and Equitable Access to Veklury for COVID-19 Patients in EU and EEA Countries -- FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences and the ...
-
-- Veklury Is First and Only FDA-Approved Treatment for COVID-19 in the United States -- -- Veklury Shortened Time to Recovery By Five Days in Hospitalized COVID-19 Patients -- ...
-
-- Real-World Evidence from More than 850,000 Hospitalized Patients Provides Clinical Insights on the Use of Veklury (Remdesivir) as Standard-of-Care COVID-19 Treatment -- -- New ...
-
– Veklury Was Associated With a Lower Risk of Developing Long-COVID in One Analysis – – Veklury Was Associated With a Reduced Risk of Mortality Among People Who Are Immunocompromised in a Separate ...
-
-- Veklury is Now the First Approved Antiviral Treatment for Patients Across all Stages of Renal Disease -- FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today ...
-
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company will donate 100,000 vials of Veklury® (remdesivir) to help address the recent surge of COVID-19 ...